The National Cancer Institute

The National Cancer Institute has awarded a three-year, $1.9 million grant to Lucid Inc. of Rochester, N.Y., to evaluate the company’s VivaScope in vivo confocal microscopy technology for the diagnosis of pigmented lesions. The study will involve approximately 600 patients in New York and California. The instrument is a noninvasive skin imaging tool with cellular resolution that may in the future eliminate the need for skin biopsy.





LATEST NEWS

• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024
• Celestial Surface Mapping Tech Combines Established Techniques
  Apr 30, 2024
• TSMC Partnerships Target Integrated Photonics Capabilities
  Apr 30, 2024
• CLEO Heads to the East Coast
  Apr 29, 2024
• Qubits Could be Stored in Flash-Like Memory
  Apr 29, 2024